EN | RU
EN | RU

Help Support

Back

Bayesian network meta-analysis comparing efficacy and safety of two JAK inhibitors in RA

Bayesian network meta-analysis comparing efficacy and safety of two JAK inhibitors in RA Bayesian network meta-analysis comparing efficacy and safety of two JAK inhibitors in RA
Bayesian network meta-analysis comparing efficacy and safety of two JAK inhibitors in RA Bayesian network meta-analysis comparing efficacy and safety of two JAK inhibitors in RA

In RA patients with inadequate response to DMARDs or biologics the relative effectiveness and safety outcomes of tofacitinib and baricitinib were identified in this study.

See All

Key take away

This study reported that tofacitinib 10mg + MTX and baricitinib 4mg + MTX were the most efficacious interventions for RA patients with inappropriate response to DMARDs or biologics therapy. Also, they do not showed significant SAEs. But, long-term studies are awaited in a large number of patients with active RA that is inadequately responsive to MTX or biologics to determine the relative efficacy and safety of tofacitinib and baricitinib.

Background

In RA patients with inadequate response to DMARDs or biologics the relative effectiveness and safety outcomes of tofacitinib and baricitinib were identified in this study.

Method

The Bayesian network meta-analysis was carried out and the evidence from RCTs was combined to evaluate the safety and efficacy of baricitinib and tofacitinib in combination with DMARDs in RA patients with an inadequate DMARD or biologics. 

Result

It was found out that as per ACR20 response the Tofacitinib 10 mg + methotrexate and baricitinib 4 mg + methotrexate was ranked the most efficacious for active RA with an inadequate DMARD or biologic response. Then was the efficacy of baricitinib 2 mg + methotrexate, tofacitinib 5 mg + methotrexate, and adalimumab + methotrexate. There was no notable difference in the incidence of serious adverse events after all the evaluated treatments.

Conclusion

In this analysis, it was observed that tofacitinib 10 mg + MTX and baricitinib 4 mg + MTX were the most effective treatments in active RA patients with an inadequate DMARD or biologic response and have no significant risk of serious adverse events.

Source:

Zeitschrift für Rheumatologie

Article:

Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.

Authors:

S.-C. Bae, Y. H. Lee

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: